Iterum Therapeutics (ITRM) has disclosed a new risk, in the Sales & Marketing category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Iterum Therapeutics faces a significant business risk as it lacks established sales, marketing, and distribution capabilities, which may hinder the successful commercialization of ORLYNVAH™ and sulopenem in additional indications. Despite receiving FDA approval for ORLYNVAH™ and engaging a financial advisor to explore strategic alternatives, the company remains without the necessary infrastructure or experience to directly market their products. If they fail to develop these capabilities or secure favorable third-party arrangements, their operating results could suffer due to delays or increased costs. The company’s ability to maximize shareholder value depends on effectively navigating these challenges and potentially collaborating with partners who possess relevant commercialization expertise.
Overall, Wall Street has a Moderate Buy consensus rating on ITRM stock based on 1 Buy.
To learn more about Iterum Therapeutics’ risk factors, click here.